ARWR - J&J returns rights to NASH RNAi candidate to Arrowhead Pharmaceuticals

• Johnson & Johnson's ( NYSE: JNJ ) Janssen unit has relinquished rights to a RNAi candidate for non-alcoholic steatohepatitis ( NASH ), returning rights to Arrowhead Pharmaceuticals ( NASDAQ: ARWR ).
• The candidate, ARO-PNPLA3 (formerly JNJ-75220795), is an RNAi therapeutic developed using Arrowhead's ( ARWR ) TRiM platform. It is designed to reduce liver expression of the enzyme patatin-like phospholipase domain containing 3 (PNPLA3).
• ARO-PNPLA3 is in phase 1.
• In a phase 1 study, following a single dose, the candidate showed a dose-dependent mean reduction in liver fat of up to 40% in patients homozygous for the I148M mutation.
• Read why Seeking Alpha contributor Larry Hall calls Arrowhead ( ARWR ) a buy.

For further details see: